أعضاء هيئة التدريس - جامعة بنها
Melanocortin Receptor Agonist (Corticotrophin) in Treatment of Refractory Diabetic nephropathy
• 2022
معلومات البحث
المؤلفون
1
S.S.El-sayed, 1A.E.Mansour, 1A.T.Mahmoud, 1H.G.Abdelsalam, 1
S.B.Hannalla, 1E.L.El-Shahawy
الكلمات المفتاحية
Not Available
المجلة العلمية
Not Available
الناشر
Not Available
المجلد
Not Available
العدد
Not Available
الصفحات
Not Available
publication.type
Local
رابط البحث
Not Available
المواد المرفقة
Not Available
الملخص
The points of this examination are To evaluate the reaction and adequacy of melanocortin
receptor agonist (ACTH) as a treatment for patients with stubborn diabetic nephropathy . This
examination was performed on 50 diabetic patients who went to inner medication division at banha
college emergency clinic. Patients with diabetic nephropathy gave proteinuria more than 1gm/24hour
pee assortment and who are not reacting to against proteinuric measures for at any rate one month of
treatment rewarded with engineered ACTH permitting a 6 months development. Result. The essential
endpoint was the level of patients accomplishing a total reduction (
receptor agonist (ACTH) as a treatment for patients with stubborn diabetic nephropathy . This
examination was performed on 50 diabetic patients who went to inner medication division at banha
college emergency clinic. Patients with diabetic nephropathy gave proteinuria more than 1gm/24hour
pee assortment and who are not reacting to against proteinuric measures for at any rate one month of
treatment rewarded with engineered ACTH permitting a 6 months development. Result. The essential
endpoint was the level of patients accomplishing a total reduction (